LC-AMP-I1, a novel venom-derived antimicrobial peptide from the wolf spider Lycosa coelestis
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00424-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Junyao Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Molecular Biology, Hengyang Medical College, University of South China, Hengyang, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Spider Venoms, Spiders, Antimicrobial Peptides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific research project of Hunan Provincial Department of Education, Hunan Graduate Research Innovation Project, MOST | National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Antibiotic resistance has become a critical concern in recent years, and antimicrobial peptides may function as innovative antibacterial agents to address this issue. In this work, we identified a novel antimicrobial peptide, LC-AMP-I1, derived from the venom of Lycosa coelestis , demonstrating substantial antibacterial properties and minimal hemolytic activity. LC-AMP-I1 was subjected to additional assessment for antibacterial efficacy, anti-biofilm properties, drug resistance, stability, and cytotoxicity in vitro . It exhibited comparable antibacterial efficacy to melittin against six common clinical multidrug-resistant bacteria, effectively inhibiting biofilm formation and disrupting established biofilms. Additionally, LC-AMP-I1 demonstrated minimal bacterial resistance, excellent stability, negligible mammalian cell toxicity, low hemolytic activity, and appropriate selectivity for both normal and tumor cells. When combined with traditional antibiotics, LC-AMP-I1 exhibited additive or synergistic therapeutic effects. In a neutropenic mouse thigh infection model, LC-AMP-I1 exhibited a therapeutic effect in inhibiting bacterial proliferation in vivo . The mechanistic investigation indicated that LC-AMP-I1 could influence bacterial cell membrane permeability at low concentrations and directly disrupt structure-function at high concentrations. The results of this work indicate that LC-AMP-I1 may function as a viable alternative to traditional antibiotics in addressing multidrug-resistant bacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry and Molecular Biology, Hengyang Medical College, University of South China, Hengyang, China.
- The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, China.
- Hunan Key Laboratory for Conservation and Utilization of Biological Resources in the Nanyue Mountainous Region, College of Life Sciences, Hengyang Normal University, Hengyang, China.
ORCID-Profile: Xing Tang, Huaxin Tan
Förderung
- Scientific research project of Hunan Provincial Department of Education
- Hunan Graduate Research Innovation Project
- MOST | National Natural Science Foundation of China (NSFC)
- Open Fund project of Hunan Key Laboratory for Conservation and Utilization of Biological Resources in the Nanyue Mountainous Region
Zitieren
APA
Wang, J., Liu, X., Song, Y., Liu, Z., Tang, X., & Tan, H. (2025). LC-AMP-I1, a novel venom-derived antimicrobial peptide from the wolf spider Lycosa coelestis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00424-24
Vancouver
Wang J, Liu X, Song Y, Liu Z, Tang X, Tan H. LC-AMP-I1, a novel venom-derived antimicrobial peptide from the wolf spider Lycosa coelestis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00424-24
BibTeX
@article{Wang2025,
author = {Wang, Junyao and Liu, Xi and Song, Yuxin and Liu, Zhonghua and Tang, Xing and Tan, Huaxin},
title = {LC-AMP-I1, a novel venom-derived antimicrobial peptide from the wolf spider Lycosa coelestis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00424-24}
}
EUVIMED